Cost-effectiveness analysis of molecular testing in minimally invasive samples to detect endometrial cancer in women with postmenopausal bleeding.

"Competing interests The authors declare no competing interests."

"Funding This work was conducted with the contribution of the Carlos III Health Institute through projects PIE16/0049, PI17/01179, PI18/01137, PI19/01118 and PI19/01835, as well as through CIBERESP CB06/02/0073, CIBERONC CB16/12/00231, CIBERONC CB16/12/00234, CM19/00216, FI20/00031, MV20/00029 and MV21/00061, co-financed by the European Regional Development Fund ERDF, a way to build Europe, through payments to the institution the authors work for. It also counts with the support of the Secretariat for Universities and Research of the Department of Business and Knowledge of the Generalitat de Catalunya grants to support the activities of research groups 2021SGR01029, 2021SGR01354 and 2017SGR00735, AECC Grupos estables coordinados, and also with funding from the Health Department of the Generalitat de Catalunya (PERIS SLT006/17/76), through payments to the institution the authors work for. We thank CERCA Programme/Generalitat de Catalunya for institutional support. Laura Costas has received speaker honoraria from Roche (personal payment). Laura Costas has received supplies from Integrated DNA Technologies—IDT- and Roche Diagnostics at 50% discount for a pilot study for the development of a molecular test for endometrial cancer early detection. Silvia de Sanjosé is participating on a Data Safety Monitoring Board of the randomised clinical trial in Zambia evaluating the management of cervical precancer. Role of the funding sources: None of the funding sources had a role on study’s design, conduct and reporting."